Introduction: Endocardial radiofrequency ablation of septal hypertrophy (ERASH) is the new promising intervention method of treatment of patients with hypertrophic obstructive cardiomyopathy (HOKMP). The aim of our study is to prove safety and eficcasy of ERASH in treatment of HOKMP.
Methods: Patients with maximal pharmacology treatment of HOKMP and lasting high gradient in left ventricle outflow tract (LVOTG) and limitation by symptoms are indicated to intervention treatment.
Results: From september 2018 up to september 2021 there were 6 patients who underwent ERASH with average age 58 years. Average rest LVOTG was 99mmHg and 115mmHg after Valsava. Resulting average LVOTG after procedure was 21mmHg in rest and 57,5mmHg provoced. In 6 months follow up 63mmHg resting and 72mmHg provoced. In two patients there was periprocedural pericardial effusion presented with pericardial drenage, one due to temporary pacemaker, and one permanent pacemaker implant due to AVB III. degree.
Conclusion: ERASH seems to be promising new method in interventional treatment of HOKMP with similar efficacy and safety compare to ASA. Higher amount of complications was probably due to previous ASA procedure and learning curve